Abstract 672: Pharmacokinetic and pharmacodynamic (PK/PD) modeling of preclinical data of a novel anti-fibroblast growth factor receptor 2(FGFR2) antibody (BAY 1179470) to guide dosing in Phase 1

2014 ◽  
Author(s):  
Sabine Wittemer-Rump ◽  
Charlotte Kopitz ◽  
Hung Huynh ◽  
Lars Lindbom ◽  
Bernhard Beckermann ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Phase 1 ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Preclinical Data

Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2501-2501 ◽  
Author(s):  
Rastislav Bahleda ◽  
Rodrigo Dienstmann ◽  
Barbara Adamo ◽  
Anas Gazzah ◽  
Jeffrey R. Infante ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Solid Tumors ◽  
Fibroblast Growth Factor Receptor ◽  
Phase 1 ◽  
Growth Factor Receptor ◽  
Advanced Solid Tumors ◽  
Fibroblast Growth ◽  
Phase 1 Study

A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2620-2620 ◽  
Author(s):  
Hendrik-Tobias Arkenau ◽  
Matilde Saggese ◽  
Antoine Hollebecque ◽  
Alastair Mathewson ◽  
Charlotte Rose Lemech ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Phase 1 ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Expansion Cohort
Sign in / Sign up

Export Citation Format

Share Document